IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab

Summary

This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2 mg followed by 2q8 IAI for a total of 52 weeks; only one study eye from each patient will be enrolled.

Timeline

Start

2015-06

Primary completion

2018-12

Completion

2018-12-12

Drugs

Indications